ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
31 hedge funds and large institutions have $3M invested in ImmunoCellular Therapeutics, Ltd. in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 12 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
16% less capital invested
Capital invested by funds: $3.57M → $3M (-$571K)
21% less funds holding
Funds holding: 39 → 31 (-8)
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$226K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$78.3K |
| 3 |
Renaissance Technologies
New York
|
+$75.1K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.2K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$26.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$148K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$85.4K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$62K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$57K |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$45K |
IMUC Hedge Fund Activity: Q4 2014 in Review
31 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q4 2014, worth a combined $3M — down 16% from $3.57M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of IMUC and 5 opened new positions — a net loss of 7 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $226K. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $148K sold.
- 31 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q4 2014, down from 39 in Q3 2014.
- Funds reported $3M of ImmunoCellular Therapeutics, Ltd. stock for Q4 2014, down 16% quarter-over-quarter.
- 5 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q4 2014 and 12 closed out, a net change of -7 holders.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q4 2014 was Jacobs Levy Equity Management, an estimated $226K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q4 2014 was D.E. Shaw & Co, an estimated $148K sold.
Based on aggregated 13F filings for Q4 2014.